Colgate-Palmolive (NYSE: CL) has proved remarkably resilient during the pandemic as first-quarter sales rose 5.5% from last year and profits bounded 28% higher.
Because the personal care products giant generates around 70% of its revenue from international markets, and 45% of total sales came from emerging markets in the first quarter, its business has performed admirably despite widespread exposure to the impacts caused by the coronavirus.
But that was virtually all before COVID-19 was formally declared a pandemic in late March, so let's take a closer look to see if, after the ravages of the crisis that traveled around the world, Colgate stock is a buy.
Source Fool.com